Detalhe da pesquisa
1.
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.
Lancet
; 402(10418): 2197-2208, 2023 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37871604
2.
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
JAMA Oncol
; 4(5): e180013, 2018 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29543932